• Applied Cisplatin (CDDP) Workflows: From Xenografts to Resis

  2026-08-07

  Cisplatin (CDDP) remains the gold standard for dissecting DNA crosslinking-driven apoptosis and tumor growth inhibition in cancer research. This deep-dive article translates recent mechanistic advances into actionable workflows, troubleshooting strategies, and next-gen resistance studies, leveraging APExBIO’s trusted product.

• Optimizing Cancer Epigenetics with GSK126 EZH2 Inhibitor (SK

  2026-08-06

  This article delivers a scenario-driven, evidence-based exploration of GSK126 EZH2 inhibitor (SKU A3446) for cancer epigenetics research. It addresses real laboratory challenges in cell viability and cytotoxicity assays, highlighting how the compound’s high selectivity and robust performance improve reproducibility, workflow efficiency, and data quality.

• ELAVL3/MYCN Feedback in NEPC: Mechanisms and Therapeutic Tar

  2026-08-06

  This study identifies a positive feedback loop between ELAVL3 and MYCN as a key driver of neuroendocrine prostate cancer (NEPC) phenotype and progression. By elucidating the molecular mechanisms underpinning NEPC and demonstrating pharmacological intervention possibilities, the work provides a foundation for new targeted therapy approaches.

• Plerixafor (AMD3100): Advancing CXCR4 Inhibition in Research

  2026-08-05

  Plerixafor (AMD3100) is the benchmark small-molecule CXCR4 antagonist for dissecting the CXCL12/CXCR4 axis in cancer, stem cell, and immunology research. This guide delivers actionable protocols, troubleshooting, and evidence-driven workflow enhancements for maximizing the impact of Plerixafor in advanced experimental studies.

• Paclitaxel (Taxol) Workflows in Cancer and Neuropathy Models

  2026-08-05

  Paclitaxel (Taxol) is a cornerstone for dissecting cell cycle arrest and antitumor mechanisms in both in vitro and in vivo research. This article delivers benchmarked workflows, advanced applications, and troubleshooting strategies, including how recent innovations in mRNA therapy leverage paclitaxel-induced neuropathy models for translational gains.

• Unlocking Resistance: L1023 Anti-Cancer Compound Library in

  2026-08-04

  Explore how the L1023 Anti-Cancer Compound Library empowers advanced research into drug resistance mechanisms such as MCL1-mediated survival, supporting high-throughput screening and precision oncology. This article delves deeper than existing content, spotlighting translational insights and protocol guidance.

• CRISPRi Targeting of Fabp4 in Adipocytes: Obesity and Liver

  2026-08-04

  This study introduces a targeted, nonviral CRISPR interference (CRISPRi) system against Fabp4 in white adipocytes, resulting in significant amelioration of obesity, inflammation, hepatic steatosis, and insulin resistance in vivo. The innovation addresses long-standing delivery and specificity challenges in metabolic disease research, offering new mechanistic and translational directions.

• NSC-23766: Rac GTPase Inhibitor for Advanced Cancer Research

  2026-08-03

  NSC23766 trihydrochloride empowers researchers to dissect Rac1-driven oncogenic signaling with precision, supporting both mono- and co-targeted approaches in breast cancer and beyond. Its selective inhibition profile, robust solubility, and workflow versatility make it indispensable for mechanistic studies, apoptosis induction, and translational protocol development.

• Cy5-UTP: Illuminating RNA Vaccines and Translational Discove

  2026-08-03

  This thought-leadership article examines how Cy5-UTP (Cyanine 5-UTP) empowers the next generation of RNA probe design, with a focus on its application in advanced translational research such as circular RNA-based immunotherapies. Bridging mechanistic insights, strategic workflow choices, and emerging clinical relevance, we contextualize Cy5-UTP’s unique value for researchers navigating the evolving landscape of RNA therapeutics and molecular diagnostics. Building on recent innovations in neoantigen circRNA vaccines, the discussion integrates experimental best practices, competitive differentiators, and a forward-looking assessment of fluorescent RNA labeling in the precision medicine era.

• BMN 673 (Talazoparib) in DNA Repair Deficiency Research

  2026-08-02

  BMN 673 (Talazoparib) stands out as a high-potency PARP1/2 inhibitor, enabling robust modeling of homologous recombination deficient cancer treatment and advanced DNA repair targeting. This guide distills actionable protocols, innovative assay designs, and troubleshooting insights, translating recent spliceosome research into practical laboratory strategies.

• GLP-1 (9-36) Amide: Precision Antagonism in GLP-1R Signaling

  2026-08-01

  GLP-1 (9-36) amide empowers metabolic and diabetes researchers with unmatched selectivity for dissecting glucagon-like peptide-1 receptor pathways. This article delivers actionable workflows, troubleshooting insights, and novel reference-backed protocols for leveraging GLP-1 (9-36) amide in advanced GPCR signaling studies.

• Dissecting Cancer Drug Responses: Innovations in In Vitro As

  2026-07-31

  Schwartz's dissertation establishes a systematic framework to distinguish between proliferative arrest and cell death when evaluating anti-cancer agents in vitro. This methodological advance enables more precise interpretation of drug efficacy, informing translational research and assay reproducibility across preclinical cancer studies.

• U 46619: Mechanistic Tool for Platelet Aggregation and Vascu

  2026-07-31

  U 46619 (11,9 epoxymethano-prostaglandin H2) is a selective TP receptor agonist widely used as a benchmark platelet aggregation inducer. Its well-characterized EC50 values enable reproducible modeling of cardiovascular signaling and renal hemodynamics. This article details its mechanism, application bounds, and protocol integration for translational research.

• Machine Learning for Predicting Lipid Nanoparticles in mRNA

  2026-07-30

  This study pioneers the use of machine learning to predict optimal lipid nanoparticle formulations for mRNA vaccine delivery, dramatically accelerating the screening of ionizable lipids. The model demonstrates high predictive accuracy and provides actionable insights for rational design, as validated by experimental comparisons between SM-102 and other lipids.

• Dabigatran etexilate: Direct Thrombin Inhibitor for Anticoag

  2026-07-30

  Dabigatran etexilate is a potent oral direct thrombin inhibitor with a well-characterized mechanism and predictable anticoagulant effects. It is widely used in research on atrial fibrillation and stroke prevention, offering rapid, selective thrombin modulation without the need for routine monitoring. APExBIO supplies Dabigatran etexilate (A8381) for high-reliability experimental workflows.

15105 records 1/1007 page Next 12345 下5页 Last page